ADO 0.00% 2.1¢ anteotech ltd

validation of anteobind with ellume partnership, page-13

  1. 443 Posts.
    lightbulb Created with Sketch. 105
    With anteobind being the key ingredient to make this tests work, Will there be an increase in sales for anteobind from quarterly report?

    Looks like these projects will be fully funded..... anteo just need to supply its sauce

    Once the tests are in production = royalty payments?

    Ellume gsk partnership is for the flu test? Product is ready for sale? But needs scale up for mass production in particularly the US?

    #####Medical diagnostics firm Ellume gets German backing for TB testing
    Brisbane medical diagnostics company Ellume has received a $US15 million ($21m) investment from German biotech Qiagen as part of a broader strategic partnership between the two companies to detect tuberculosis. ######




    Clinical trials for a tuberculosis testing solution will begin this year with commercialisation next year.
    The companies are targeting Asia, Africa and Latin America, which suffer from high rates of the bacterial infection.
    A group of 30 countries in the three regions represent 85 per cent of all tuberculosis cases, according to World Health Organisation data.
    “We are confident that Ellume’s technology will assist Qiagen with detection of TB infections, leading to earlier identification and more effective treatment and containment in low-resource, high-burden countries,” Ellume founder and managing director Sean Parsons said ahead of today’s formal announcement of the partnership.



    ######The new partnership follows a deal in December with pharmaceutical giant GSK for digital consumer products focused on respiratory care. The company chief said then that
    he would seek a market listing in the next 12 to 18 months to attract the capital needed to scale up the commercialisation of the professional-use product in the US.######





    The Qiagen tie-up includes the use of Ellume’s intellectual property and aims to detect latent tuberculosis where a bacterial infection is present but produces no symptoms unless it moves to an active disease.
    The companies may look to expand to focus on other illnesses coincident with the disease, such as HIV. “To have this second partnership with a company such as Qiagen is a real validation of the technology we’ve created over the past five years,” Dr Parsons said. He said the technology integrated a diagnosis and the tests made in that diagnosis with a pathway for the best treatment for an illness.

    https://www.ellumehealth.com/upload...-Ellume-Qiagen-partnership-for-TB-testing.pdf
 
watchlist Created with Sketch. Add ADO (ASX) to my watchlist
(20min delay)
Last
2.1¢
Change
0.000(0.00%)
Mkt cap ! $54.77M
Open High Low Value Volume
2.1¢ 2.2¢ 2.1¢ $37.13K 1.752M

Buyers (Bids)

No. Vol. Price($)
2 441468 2.1¢
 

Sellers (Offers)

Price($) Vol. No.
2.2¢ 668891 4
View Market Depth
Last trade - 16.10pm 18/11/2024 (20 minute delay) ?
ADO (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.